<DOC>
	<DOCNO>NCT01975337</DOCNO>
	<brief_summary>The primary objective study compare single dose pharmacokinetics alisporivir subject end stage renal disease ( ESRD ) hemodialysis match healthy subject . The secondary objective evaluate safety tolerability single dose alisporivir administer subject ESRD .</brief_summary>
	<brief_title>Pharmacokinetics Safety Alisporivir Subjects With End Stage Renal Disease Hemodialysis Compared Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Provides write informed consent assessment perform Matched healthy participant good health determine past medical history , physical examination , vital sign , laboratory test , assessment ESRD participant protocoldefined stable hemodialysis regimen evidence hepatic decompensation , vital sign test within protocolspecified limit Weighs least 50 kg Is able communicate well investigator , understand comply requirement study . Has history current use overthecounter medication , dietary supplement , drug ( include nicotine alcohol ) outside protocolspecified parameter Has sign , symptom history condition , per protocol opinion investigator , might compromise : 1. safety wellbeing participant study staff ; 2. safety wellbeing participant 's offspring ( pregnancy breastfeed ) ; 3. analysis result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>